**References**

1. www.cebm.net

2. Empfehlungen Gynäkologische Onkologie Kommission Mamma, 2020; www.ago-online.

3. Marc P. McRae. The Benefits of Dietary Fiber Intake on Reducing the Risk of Cancer: An Umbrella Review of Meta-analyses. Nutr J. 2018 Sep 21;17(1):87. doi: 10.1186/s12937-018-0394-2

4. de Boer MC, Wörner EA, Verlaan D,et al. The Mechanisms and Effects of Physical Activity on Breast Cancer. Clin Breast Cancer. 2017 Jul;17(4):272-278. doi: 10.1016/j.clbc.2017.01.006. Epub 2017 Jan 24

5. Manson JE, Aragaki AK, Rossouw JE et al.: Menopausal hormone therapy and long-term all-cause and cause-specific mortality, the women´s health initiative randomized trials. JAMA 2017; 318: 927-938

6. Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566. doi:10.1093/annonc/mdz012

7. Hurvitz SA, Gonçalves A, Rugo HS, et al. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial [published online ahead of print, 2019 Nov 25]. Oncologist. 2019; The Oncologist.2019-0493. doi:10.1634/theoncologist.2019-0493

8. Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, Genepso, Nogues C, Gauthier-Villars M, Caron O, Gesta P et al: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2020, 22(1):8.

9. Heemskerk-Gerritsen BAM, Jager A, Koppert LB, Obdeijn AI, Collee M, Meijers-Heijboer HEJ, Jenner DJ, Oldenburg HSA, van Engelen K, de Vries J et al: Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2019, 177(3):723-733.

10. Bick U, Engel C, Krug B, Heindel W, Fallenberg EM, Rhiem K, Maintz D, Golatta M, Speiser D, Rjosk-Dendorfer D, Lämmer-Skarke I, Dietzel F, Schäfer KWF, Leinert E, Weigel S, Sauer S, Pertschy S, Hofmockel T, Hagert-Winkler A, Kast K, Quante A, Meindl A, Kiechle M, Loeffler M, Schmutzler RK; German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat. 2019 May;175(1):217-228. doi: 10.1007/s10549-019-05152-9. Epub 2019 Feb 6. PMID: 30725383.

11. https://healthcare-quality.jrc.ec.europa.eu/european-breast-cancer-guidelines/screening-ages-and-frequencies12. Phi X-A, Tagliafico A, Houssami N et al. Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts – a systematic review and meta-analysis. BMC Cancer201818:380; https://doi.org/10.1186/s12885-018-4263-3

13. Supplemental MRI Screening for Women with Extremely Dense Breast Tissue.Bakker MF, de Lange SV, Pijnappel RM, Mann RM, Peeters PHM, Monninkhof EM, Emaus MJ, Loo CE, Bisschops RHC, Lobbes MBI, de Jong MDF, Duvivier KM, Veltman J, Karssemeijer N, de Koning HJ, van Diest PJ, Mali WPTM, van den Bosch MAAJ, Veldhuis WB, van Gils CH; DENSE Trial Study GroupN Engl J Med. 2019 Nov 28;381(22):2091-2102. doi: 10.1056/NEJMoa1903986.

 14 Dromain, C., N. Vietti-Violi, and J.Y. Meuwly, Angiomammography: A review of current evidences. Diagn Interv Imaging, 2019.

15. Mariscotti G, Durando M, Tagliafico A, Campanino PP, Bosco D, Casella C, Bussone R, Ala A, Castellano I, Sapino A, Bergamasco L, Fonio P, Houssami N.Preoperative breast cancer staging with multi-modality imaging and surgical outcomes. Eur J Radiol. 2020 Jan;122:108766. doi: 10.1016/j.ejrad.2019.108766. Epub 2019 Nov 22. Erratum in: Eur J Radiol. 2020 Feb 26;:108919.

16. WHO Classification of Breast Tumours. Fifth Edition 2019

17. Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, Barrio A, Morrow M. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018 Jun;25(6):1488-1494.

18. Sinn P, Brucker SY, Budach W, et al: DCIS und Risikoläsionen; in Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms (Hrsg: Leitlinienprogramm Onkologie der AWMF, DKG und DKH), 2017, pp 79-89

19. Khan S, Diaz A, Archer KJ, Lehman RR, Mullins T, Cardenosa G, Bear HD. Papillary lesions of the breast: To excise or observe? Breast J. 2018 May;24(3):350-355

20. Rageth CJ, O`Flynn EAM, Pinker K et al.: Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Review, Breast Cancer Res Treat, 2018, doi: 10.1007/s10549-018-05071-1

21. DeCensi A, Puntoni M, Guerrieri-Gonzaga A et al.: Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. J Clin Oncol. 2019 Jul 1;37(19):1629-1637. doi: 10.1200/JCO.18.01779. Epub 2019 Apr 11

22. Nicolini A, Ferrari P, Duffy MJ. Prognostic and predictive biomarkers in breast cancer: Past, present and future. Semin Cancer Biol. 2018;52(Pt 1):56–73.

23. Sestak I, Buus R, Cuzick J, et al. (2018) Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 4:545-553.

24. Schmid P, Adams S, Rugo HS, et al. (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 379:2108-2121.

25. André F, Ciruelos E, Rubovszky G, Campone M et al. (2019) Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 380:1929-1940. doi: 10.1056/NEJMoa1813904

26. Hyman DM, Piha-Paul SA, Won H, et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194. doi: 10.1038/nature25475

27. Fribbens C, Garcia Murillas I, Beaney M et al. (2018) Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol.29:145-153. doi: 10.1093/annonc/mdx483

28. Narod SA, Iqbal J, Giannakeas V, et al.: Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888-896

29. So A, De La Cruz LM, Williams AD et al.: Impact of preoperative magnetic resonance imaging and lumpectomy cavity shavings on re-excision rate in pure ductal carcinoma in situ-A single institution's experience. J Surg Oncol. 2018 Mar; 117(4): 558-566.

30. Kuerer HM, Smith BD, Chavez-MacGregor M, et al.: DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017;8(14):2653-2662

31. Solin LJ, Gray R, Hughes LL, et al. Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol 2015; 33:3938

32. McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 2015; 33:709

 33. Giuliano AE, Ballman KV, McCall L, et al.: Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017 Sep 12;318(10):918-926.

34. Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310.

35. Moo TA, Edelweiss M, Hajiyeva S, et al. Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection? Ann Surg Oncol. 2018;25(6):1488–1494

36. Tee SR, Devane LA, Evoy D et al. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. Br J Surg. 2018 Nov;105(12):1541-1552

37. Caudle AS, Yang WT, Krishnamurthy S, et al.: Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients with Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016 Apr 1;34(10):1072-8

38. Bertozzi N, Pesce M, Santi PL, et al: Oncoplastic breast surgery: comprehensive review. Eur Rev Med Pharmacol Sci 2017; 21(11):2572-2585

39. Li Y, Xu G, Yu N, Huang J, Long X Prepectoral versus Subpectoral Implant-Based Breast Reconstruction: A Meta-analysis. Ann Plast Surg. 2020 Jan 6. doi: 10.1097/SAP.0000000000002190.

40. Li L Su Y, Xiu B, Huang X, Chi W, Hou J, Zhang Y, Tian J, Wang J, Wu J. Should obesity be considered a contraindication for prepectoral breast :Comparison of prepectoral and subpectoral breast reconstruction after mastectomies: A systematic review and meta analysis. Eur J Surg Oncol. 2019 Sep;45(9):1542-1550. doi: 10.1016/j.ejso.2019.05.015.

 41. Collett DJ, Rakhorst H, Lennox P,et al.: Current Risk Estimate of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Textured Breast Implants. Plast Reconstr Surg. 2019 Mar;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):30S-40S. doi: 10.1097/PRS.0000000000005567).

42. Cardoso MJ, Wyld L, Rubio IT, et al EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. Breast. 2019 Apr;44:90-93. doi: 10.1016/j.breast.2019.01.011).

43. Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014: 384; 164

44. EBCTCG: Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol pii: S1470-2045(17)30777-5, 2017

45. Loibl S, Weber KE, Timms KM, et al "Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto Ann Oncol 2018;29:2341-2347.

46. Sikov WM, Berry DA, Perou CM, et al: Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13-21. doi: 10.1200/JCO.2014.57.0572. Epub 2014

47. Untch M, Jackisch C, Schneeweiss A, et al. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. J Clin Oncol 2019. 37:2226-223493. Gianni L, Pienkowski T, Im YH, et al.: 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016 Jun;17(6):791-800.

48. Schneeweiss A, Chia S, Hickish T et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 2017, 89:27-35

49. Loibl S, Werutsky G, Nekljudova V, et al. Impact in delay of start of chemotherapy and surgery on pCR and survival in breast cancer – a pooled analysis of individual patient data from six prospectively randomized neoadjuvant trials. ASCO 2017 (abs 571)

50. Masuda N, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017, 376, 2147–2159

51. von Minckwitz G, Huang CS, Mano MS, et al. (KATHERINE Investigators): Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017

52. Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432-44.

53. Early Breast Cancer Trialists' Collaborative G. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393(10179):1440-52.

54. Möbus V, Jackisch C, Lück HJ, du Bois A, Thomssen C, Kuhn W, et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018;29(1):178-85.

55. Van Mackelenbergh M, Seither F, Moebus V, O’Shaughnessy J, Martin M, Joenssu H, et al. Effects of capecitabine as part of neo/adjuvant chemotherapy. A Metaanalysis of individual patient data from 12 randomized trials including 15457 patients. SABCS 2019;abstr. GS1-07.

56. Nitz U, Gluz O, Clemens M, Malter W, Reimer T, Nuding B, et al. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J Clin Oncol. 2019;37(10):799-808.

57. de Nonneville A, Gonçalves A, Zemmour C, Cohen M, Classe JM, Reyal F, et al. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study. Eur J Cancer. 2017;84:34-43.

58. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-83.

59. Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134-41.

60. Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, et al. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019;37(22):1868-75.

61. von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;377(2):122-31.

62. M P. Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019; abstr GS 01-04.

63. Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(12):1688-700.

64. Villegas S, Lederer B: Similarities between low hormone receptor positive and hormone receptor negative breast cancer: an analysis of 4366 patients from multicenter clinical trials, SABCS 2018 P2-08-10

65. Viale G, Regan MM, Maiorano E, et al: Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25(25):3846–5

66. Francis PA, Pagani O, Fleming GF et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379: 122-137

67. Kim HA, Lee JW, Nam SJ et al. Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. J Clin Oncol. 2019

68. Strasser-Weippl K, Sudan G, Ramjeesingh R, et al.: Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. Eur J Cancer 2018; 90: 19-2569. Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, et al.: Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet 2019 Dec 14;394:2155–2164.

70. Whelan TJ, Julian JA, Berrang TS, Kim D-H, Germain I, Nichol AM, et al.: External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet 2019 Dec 14;394:2165–2172.

71. Meattini I, Saieva C, Lucidi S, Russo MI, Scotti V, Desideri I, et al. GS4-06. Accelerated partial breast or whole breast irradiation after breast conservation surgery for patients with early breast cancer: 10-year follow up results of the APBI IMRT Florence randomized phase 3 trial. Presented at San Antonio Breast Cancer Conference 2019.

72. Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, et al.: Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet 2017 Sep 9;390:1048–1060. 73. Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, et al.: Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer 2015 Mar;51:451–463.74. Wedam S, Fashoyin-Aje L, Bloomquist E, et al.:FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer. Clin Cancer Res. 2019 Oct 24. doi: 10.1158/1078-0432.CCR-19-2580).75. Choi N, Kim K, Shin KH, et al.: The Characteristics of Local Recurrence After Breast-Conserving Surgery Alone for Malignant and Borderline Phyllodes Tumors of the Breast (KROG 16-08). Clin Breast Cancer. 2019 Oct;19(5):345-353.e2. doi: 10.1016/j.clbc.2019.04.003; Spanheimer PM, Murray MP, Zabor EC, et al.: Long-Term Outcomes After Surgical Treatment of Malignant/ Borderline Phyllodes Tumors of the Breast. Ann Surg Oncol (2019) 26:2136–2143 https://doi.org/10.1245/s10434-019-07210-4)

76. Choi N, Kim K, Shin KH, et al.: The Characteristics of Local Recurrence After Breast-Conserving Surgery Alone for Malignant and Borderline Phyllodes Tumors of the Breast (KROG 16-08). Clin Breast Cancer. 2019 Oct;19(5):345-353.e2. doi: 10.1016/j.clbc.2019.04.003; Spanheimer PM, Murray MP, Zabor EC, et al.: Long-Term Outcomes After Surgical Treatment of Malignant/ Borderline Phyllodes Tumors of the Breast. Ann Surg Oncol (2019) 26:2136–2143)

 77. Schlüter K, Schneider J, Sprave T, Wiskemann J, Rosenberger F. Feasibility of Two High-Intensity Interval Training Protocols in Cancer Survivors. Med Sci Sports Exerc. 2019 Dec;51(12):2443-2450

78. Hall DL, Luberto CM, Philpotts et al., Mind-body interventions for fear of cancer recurrence: A systematic review and meta-analysis. Psycho-Oncology 2018; 1-13

79. Ertz-Archambault NM, Rogoff LB, Kosiorek HE, Ernst BJ, Anderson KS, Pockaj BA, Gray RJ, Northfelt DW: Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival. Support Care Cancer 2019.

80. Heudel PE, Van Praagh-Doreau I, Duvert B, Cauvin I, Hardy-Bessard AC, Jacquin JP, Stefani L, Vincent L, Dramais D, Guastalla JP, Blanc E, Belleville A, Lavergne E, Perol D: Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial. Support Care Cancer 2019, 27:1879-89.

81. Lahart IM, Metsios GS, Nevill AM, Carmichael AR: Physical activity for women with breast cancer after adjuvant therapy. Cochrane Database Syst Rev 2018, 1:Cd011292.

82. Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD: Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial. Jama 2018, 320:167-76.

83. Athanasiou S, Pitsouni E, Douskos A, Salvatore S, Loutradis D, Grigoriadis T: Intravaginal energy-based devices and sexual health of female cancer survivors: a systematic review and meta-analysis. Lasers Med Sci 2019.

84.Shah C, Ahlawat S, Khan A et al.. The Role of MRI in the Follow-up of Women Undergoing Breast-conserving Therapy. Am J Clin Oncol. 2016 Jun;39(3):314-9

85. Runowcz CD, Leach CR, Henry L et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. CA Cancer J Clin 2016; 66:43-73

86. Poodt IGM, Schipper RJ, de Greef BTA, Vugts G, Maaskant-Braat AJG, Jansen FH, et al. Sentinel Node And Recurrent Breast Cancer (SNARB) Research Group. Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval. Breast Cancer Res Treat. 2019;175(2):419-428.

87. Haffty BG, McCall LM, Ballman KV, Buchholz TA, Hunt KK, Boughey JC. Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial. Int J Radiat Oncol Biol Phys. 2019;5(1):174-182.

88. Peng G, Zhou Z, Jiang M, Yang F. Can a subgroup at high risk for LRR be identified from T1-2 breast cancer with negative lymph nodes after mastectomy? A meta-analysis. Biosci Rep. 2019;39(9).

89. Bounous VE, Novara L, Scicchitano F, Villasco A, Maggiorotto F, Ponzone R, et al; A retrospective analysis on 197 cases of breast cancer local recurrence: Biology, treatment, and prognosis. Breast J. 2019 Nov 25. doi: 10.1111/tbj.13698

90. Forster T, Akbaba S, Schmitt D, Krug D, El Shafiie R, Oelmann-Avendano J, et al. Second breast conserving therapy after ipsilateral breast tumor recurrence - a 10-year experience of re-irradiation. J Contemp Brachytherapy. 2019;11(4):312-319.

91. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379:2108-2121.

92. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33:244-50.

93. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380:1929-1940.

94. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018;554:189-194.

95. Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O’Leary B, Kilburn L, et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol. 2018;29:145-153.

96. Fribbens C, O'Leary B, Kilburn L et al. (2016) Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol. 34:2961-8

97. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731-747.

98. Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular targets (ESCAT). Ann Oncol. 2019 Mar 1;30(3):365-373.

99. Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;10:1758835918793326. doi: 10.1177/1758835918793326. eCollection 2018. Review. Erratum in: Ther Adv Med Oncol. 2018 Dec 03;10:1758835918810116.

100. Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr Oncol Rep. 2019;21(3):25.

101. Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019;381(4):307-316.

102. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;3882(6):514-524

103. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol. 2019 Sep 29. doi: 10.1001/jamaoncol.2019.4782. [Epub ahead of print]

104. Robson M, Goessl C, Domchek S. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017;377(6):523-533.

105. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018;379(8):753-763.

106. Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558-566.

107. Pivot X, Im SA, Guo M, Marmé F. Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer 2018;25(3):370-374.

108. Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. [4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.](https://www.ncbi.nlm.nih.gov/pubmed/30032243) Ann Oncol. 2018;29(8):1634-1657.

109. Coleman RE. Bone cancer in 2011: prevention and treatment of bone metastases. Nat Rev Clin Oncol. 2011;9:76–78.

110. Tesfamariam Y, Jakob T, Wöckel A, Adams A, Weigl A, Monsef I, et al. Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2019;137:1-8.

111. Awan AA, Hutton B, Hilton J, Mazarello S, van Pznak C, Vandermeer L, et al. De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019;176(3):507-517.

112.https://www.onkosupport.de/asors/content/e4126/e1743/e1861/e1862/e4628/LaufzettelAGSMOFarbefinal.pdf

113. Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Research 2016;18(1):8.

114. Witzel I, Laakmann E, Weide R, Neunhoffer T, Park-Simon TJ, Schmidt M, et al. Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. Eur J Cancer 2018;102:1-9.

115. Hulsbergen AFC, Claes A, Kavouridis VK, Ansaripour A, Nogarede C, Hughes ME, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. [Neuro Oncol.](https://www.ncbi.nlm.nih.gov/pubmed/31970416) 2020 Jan 23. pii: noaa013. doi: 10.1093/neuonc/noaa013. [Epub ahead of print])

116. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18(8):1049-60.

117. Brown A, Asher AL, Ballman K, Farace E, Cerhan J, Anderson K, et al. NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015;33(Uppl):Abstract LBA 4.

118. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2014;32(34):3810-6.

119. Badwe R, Hawaldar R, Nair N, Kaushik R, Parmar V, Siddique S, Budrukkar A, Mittra I, Gupta S. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 2015;16(13):1380-8.

120. Soran A. Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, et al. Randomized comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: Protocol MF07-01. Ann Surg Oncol. 2018;25(11):3141-3149.

121. Warschkow R, Güller U, Tarantino I, Cerny T, Schmied BM, Thuerlimann B, et al. Improved Survival After Primary Tumor Surgery in Metastatic Breast Cancer: A Propensity-adjusted, Population-based SEER Trend Analysis. Ann Surg 2016;263(6):1188-98.

122. Yoo TK, Chae BJ, Kim SJ, Lee J, Yoon TI, Lee SJ, Park HY, Park HK, Eom YH, Kim HS, Kim CJ, Shin MS, You SH, Song BJ. Identifying long-term survivors among metastatic breast cancer patients undergoing primary tumor surgery. Breast Cancer Res Treat 2017;165(1):109-118.

123. Rapiti E, Verkooijen HM, Vlastos G, et al.: Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:2743–2749.

124. Howlader M, Heaton N, Rela M: Resection of liver metastases from breast cancer: towards a manage­ ment guideline. Int J Surg 2011;9:285–291.

125. Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric­Bernstam F, Valero V, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012;151:710–716.

126. Hoffmann RT, Jakobs TF, Kubisch CH, et al.: Radiofrequency ablation after selective internal radiation therapy with yttrium90 microspheres in metastatic liver disease – is it feasible? Eur J Radiol. 2010;74:199–205.

127. Vogl TJ, Farshid P, Naguib NN, Zangos S: Thermal ablation therapies in patients with breast cancer liver metastases: a review. Eur Radiol. 2013;23:797– 804.

128. Rashid OM, Takabe K: The evolution of the role of surgery in the management of breast cancer lung metastasis. J Thorac Dis. 2012;4:420–424.

129. Tanaka K, Shimizu K, Ohtaki Y, Nakano T, Kamiyoshihara M, Kaira K, et al. Diagnosis and surgical resection of solitary pulmonary nodules in patients with breast cancer. Mol Clin Oncol. 2013;1(1):117-123.

130. Demmy TL: Optimal management of malignant pleural effusions (results of CALBG 30102). J Natl Compr Canc Netw. 2012;10:975–982.

131. Sebastian M, Kuemmel A, Schmidt M, Schmittel A: Catumaxomab: a bispecific trifunctional anti­ body. Drugs Today (Barc). 2009;45:589–597.

132. Çelik S, Lestuzzi C, Cervesato E, Dequanter D, Piotti P, De Biasio M, et al. Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions. J Thorac Cardiovasc Surg. 2014;148(5):2288-93.

133. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF Supportive Therapie bei onkologischen PatientInnen - Langversion 1.1, 2017, AWMF Registernummer: 032/054OL, http://leitlinienprogrammonkologie.de/Supportive-Therapie.95.0.html (from 18.01.2018).

134. Liu Z, Jiang L, Liang G, Song E, Jiang W, Zheng Y, Gong C. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management. J Viral Hepat. 2017;24(7):561-572.

135. Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi, et al. Olanzapine 5 mg plus standard antiemetic therapy fort he prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21(2):242-249.

136. Slimano F, Netzer F, Borget I, Lemare F, Besse B. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy. Int J Clin Pharm. 2018 Oct;40(5):1265-1271.

137. Ferrell BR, Temel JS, Temin S, Smith TJ. Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update Summary. J Oncol Pract 2017;13(2):119-121.